IBI115

IBI115 is a recombinant humanized monoclonal antibody targeting Delta-like ligand 3 (DLL3), currently under development by Innovent Biologics. DLL3 is an inhibitory Notch ligand that is highly and specifically expressed on the surface of small cell lung cancer (SCLC) and other neuroendocrine tumors, while remaining largely absent in healthy tissues. By binding specifically to DLL3, IBI115 is designed to provide a targeted therapeutic approach, potentially mediating anti-tumor activity through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) or by interfering with Notch signaling pathways. It is currently being evaluated in Phase 1 clinical trials as both a monotherapy and in combination with other agents, such as sintilimab, for the treatment of advanced SCLC.